ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000836

Prospective prevalence of pathologic gambling and medication association in Parkinson disease

Identifieur interne : 000836 ( PascalFrancis/Corpus ); précédent : 000835; suivant : 000837

Prospective prevalence of pathologic gambling and medication association in Parkinson disease

Auteurs : V. Voon ; K. Hassan ; M. Zurowski ; S. Duff-Canning ; M. De Souza ; S. Fox ; A. E. Lang ; J. Miyasaki

Source :

Neurology [ 0028-3878 ] ; 2006.

RBID : Pascal:06-0327369

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Prospective, Prévalence, Chimiothérapie.

English descriptors

KwdEn :
- Chemotherapy, Nervous system diseases, Parkinson disease, Prevalence, Prospective.

Abstract

The authors prospectively screened 297 patients with Parkinson disease (PD), who attended a tertiary clinic, using a modified South Oaks Gambling Scale. Lifetime prevalence of pathologic gambling (PG) was 3.4% and on any dopamine agonist was 7.2%. PG was associated with earlier PD onset and with dopamine agonists but not with agonist subtype or doses. We found no association with a potent D3 receptor agonist.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0028-3878`
A02	`01`			`@0 NEURAI`
A03		`1`		`@0 Neurology`
A05				`@2 66`
A06				`@2 11`
A08	`01`	`1`	`ENG`	`@1 Prospective prevalence of pathologic gambling and medication association in Parkinson disease`
A11	`01`	`1`		`@1 VOON (V.)`
A11	`02`	`1`		`@1 HASSAN (K.)`
A11	`03`	`1`		`@1 ZUROWSKI (M.)`
A11	`04`	`1`		`@1 DUFF-CANNING (S.)`
A11	`05`	`1`		`@1 DE SOUZA (M.)`
A11	`06`	`1`		`@1 FOX (S.)`
A11	`07`	`1`		`@1 LANG (A. E.)`
A11	`08`	`1`		`@1 MIYASAKI (J.)`
A14	`01`			`@1 Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health @2 Bethesda, MD @3 USA @Z 1 aut.`
A14	`02`			`@1 Department of Psychiatry, Toronto Western Hospital @2 Toronto @3 CAN @Z 1 aut. @Z 3 aut. @Z 5 aut.`
A14	`03`			`@1 Division of Neurology, Toronto Western Hospital @2 Toronto @3 CAN @Z 2 aut. @Z 4 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut.`
A20				`@1 1750-1752`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6345 @5 354000115605140300`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 10 ref.`
A47	`01`	`1`		`@0 06-0327369`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neurology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	`@0 The authors prospectively screened 297 patients with Parkinson disease (PD), who attended a tertiary clinic, using a modified South Oaks Gambling Scale. Lifetime prevalence of pathologic gambling (PG) was 3.4% and on any dopamine agonist was 7.2%. PG was associated with earlier PD onset and with dopamine agonists but not with agonist subtype or doses. We found no association with a potent D3 receptor agonist.`
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A03`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Prospective @5 09`
C03	`03`	`X`	`ENG`	`@0 Prospective @5 09`
C03	`03`	`X`	`SPA`	`@0 Prospectiva @5 09`
C03	`04`	`X`	`FRE`	`@0 Prévalence @5 10`
C03	`04`	`X`	`ENG`	`@0 Prevalence @5 10`
C03	`04`	`X`	`SPA`	`@0 Prevalencia @5 10`
C03	`05`	`X`	`FRE`	`@0 Chimiothérapie @5 11`
C03	`05`	`X`	`ENG`	`@0 Chemotherapy @5 11`
C03	`05`	`X`	`SPA`	`@0 Quimioterapia @5 11`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 212`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0327369 INIST
ET :	Prospective prevalence of pathologic gambling and medication association in Parkinson disease
AU :	VOON (V.); HASSAN (K.); ZUROWSKI (M.); DUFF-CANNING (S.); DE SOUZA (M.); FOX (S.); LANG (A. E.); MIYASAKI (J.)
AF :	Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health/Bethesda, MD/Etats-Unis (1 aut.); Department of Psychiatry, Toronto Western Hospital/Toronto/Canada (1 aut., 3 aut., 5 aut.); Division of Neurology, Toronto Western Hospital/Toronto/Canada (2 aut., 4 aut., 6 aut., 7 aut., 8 aut.)
DT :	Publication en série; Niveau analytique
SO :	Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 2006; Vol. 66; No. 11; Pp. 1750-1752; Bibl. 10 ref.
LA :	Anglais
EA :	The authors prospectively screened 297 patients with Parkinson disease (PD), who attended a tertiary clinic, using a modified South Oaks Gambling Scale. Lifetime prevalence of pathologic gambling (PG) was 3.4% and on any dopamine agonist was 7.2%. PG was associated with earlier PD onset and with dopamine agonists but not with agonist subtype or doses. We found no association with a potent D3 receptor agonist.
CC :	002B17; 002B17G; 002B17A03
FD :	Système nerveux pathologie; Parkinson maladie; Prospective; Prévalence; Chimiothérapie
FG :	Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie
ED :	Nervous system diseases; Parkinson disease; Prospective; Prevalence; Chemotherapy
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Sistema nervioso patología; Parkinson enfermedad; Prospectiva; Prevalencia; Quimioterapia
LO :	INIST-6345.354000115605140300
ID :	06-0327369

Links to Exploration step

Pascal:06-0327369

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Prospective prevalence of pathologic gambling and medication association in Parkinson disease</title>
<author><name sortKey="Voon, V" sort="Voon, V" uniqKey="Voon V" first="V." last="Voon">V. Voon</name>
<affiliation><inist:fA14 i1="01"><s1>Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychiatry, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hassan, K" sort="Hassan, K" uniqKey="Hassan K" first="K." last="Hassan">K. Hassan</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zurowski, M" sort="Zurowski, M" uniqKey="Zurowski M" first="M." last="Zurowski">M. Zurowski</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychiatry, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Duff Canning, S" sort="Duff Canning, S" uniqKey="Duff Canning S" first="S." last="Duff-Canning">S. Duff-Canning</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Souza, M" sort="De Souza, M" uniqKey="De Souza M" first="M." last="De Souza">M. De Souza</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychiatry, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fox, S" sort="Fox, S" uniqKey="Fox S" first="S." last="Fox">S. Fox</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A. E." last="Lang">A. E. Lang</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Miyasaki, J" sort="Miyasaki, J" uniqKey="Miyasaki J" first="J." last="Miyasaki">J. Miyasaki</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0327369</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0327369 INIST</idno>
<idno type="RBID">Pascal:06-0327369</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000836</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Prospective prevalence of pathologic gambling and medication association in Parkinson disease</title>
<author><name sortKey="Voon, V" sort="Voon, V" uniqKey="Voon V" first="V." last="Voon">V. Voon</name>
<affiliation><inist:fA14 i1="01"><s1>Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychiatry, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hassan, K" sort="Hassan, K" uniqKey="Hassan K" first="K." last="Hassan">K. Hassan</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zurowski, M" sort="Zurowski, M" uniqKey="Zurowski M" first="M." last="Zurowski">M. Zurowski</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychiatry, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Duff Canning, S" sort="Duff Canning, S" uniqKey="Duff Canning S" first="S." last="Duff-Canning">S. Duff-Canning</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Souza, M" sort="De Souza, M" uniqKey="De Souza M" first="M." last="De Souza">M. De Souza</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychiatry, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fox, S" sort="Fox, S" uniqKey="Fox S" first="S." last="Fox">S. Fox</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A. E." last="Lang">A. E. Lang</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Miyasaki, J" sort="Miyasaki, J" uniqKey="Miyasaki J" first="J." last="Miyasaki">J. Miyasaki</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapy</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Prevalence</term>
<term>Prospective</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Prospective</term>
<term>Prévalence</term>
<term>Chimiothérapie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The authors prospectively screened 297 patients with Parkinson disease (PD), who attended a tertiary clinic, using a modified South Oaks Gambling Scale. Lifetime prevalence of pathologic gambling (PG) was 3.4% and on any dopamine agonist was 7.2%. PG was associated with earlier PD onset and with dopamine agonists but not with agonist subtype or doses. We found no association with a potent D3 receptor agonist.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3878</s0>
</fA01>
<fA02 i1="01"><s0>NEURAI</s0>
</fA02>
<fA03 i2="1"><s0>Neurology</s0>
</fA03>
<fA05><s2>66</s2>
</fA05>
<fA06><s2>11</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Prospective prevalence of pathologic gambling and medication association in Parkinson disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>VOON (V.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HASSAN (K.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ZUROWSKI (M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DUFF-CANNING (S.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DE SOUZA (M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>FOX (S.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LANG (A. E.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MIYASAKI (J.)</s1>
</fA11>
<fA14 i1="01"><s1>Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Psychiatry, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>1750-1752</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6345</s2>
<s5>354000115605140300</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>10 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0327369</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The authors prospectively screened 297 patients with Parkinson disease (PD), who attended a tertiary clinic, using a modified South Oaks Gambling Scale. Lifetime prevalence of pathologic gambling (PG) was 3.4% and on any dopamine agonist was 7.2%. PG was associated with earlier PD onset and with dopamine agonists but not with agonist subtype or doses. We found no association with a potent D3 receptor agonist.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Prospective</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Prospective</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Prospectiva</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Prévalence</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prevalence</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Prevalencia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>212</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0327369 INIST</NO>
<ET>Prospective prevalence of pathologic gambling and medication association in Parkinson disease</ET>
<AU>VOON (V.); HASSAN (K.); ZUROWSKI (M.); DUFF-CANNING (S.); DE SOUZA (M.); FOX (S.); LANG (A. E.); MIYASAKI (J.)</AU>
<AF>Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health/Bethesda, MD/Etats-Unis (1 aut.); Department of Psychiatry, Toronto Western Hospital/Toronto/Canada (1 aut., 3 aut., 5 aut.); Division of Neurology, Toronto Western Hospital/Toronto/Canada (2 aut., 4 aut., 6 aut., 7 aut., 8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 2006; Vol. 66; No. 11; Pp. 1750-1752; Bibl. 10 ref.</SO>
<LA>Anglais</LA>
<EA>The authors prospectively screened 297 patients with Parkinson disease (PD), who attended a tertiary clinic, using a modified South Oaks Gambling Scale. Lifetime prevalence of pathologic gambling (PG) was 3.4% and on any dopamine agonist was 7.2%. PG was associated with earlier PD onset and with dopamine agonists but not with agonist subtype or doses. We found no association with a potent D3 receptor agonist.</EA>
<CC>002B17; 002B17G; 002B17A03</CC>
<FD>Système nerveux pathologie; Parkinson maladie; Prospective; Prévalence; Chimiothérapie</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie</FG>
<ED>Nervous system diseases; Parkinson disease; Prospective; Prevalence; Chemotherapy</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Sistema nervioso patología; Parkinson enfermedad; Prospectiva; Prevalencia; Quimioterapia</SD>
<LO>INIST-6345.354000115605140300</LO>
<ID>06-0327369</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000836 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000836 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0327369
   |texte=   Prospective prevalence of pathologic gambling and medication association in Parkinson disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Prospective prevalence of pathologic gambling and medication association in Parkinson disease

Prospective prevalence of pathologic gambling and medication association in Parkinson disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri